GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Quantum Si
Quantum-Si is a biotech company developing a next-generation proteomics (protein analysis) platform. Its stock price is a venture bet that its technology will revolutionize scientific research and diagnostics.
Share prices of companies in the market segment - Dna
Quantum-Si (QSI) is developing a next-generation protein sequencing platform that enables protein analysis at the single-molecule level, opening up new research opportunities. We refer to this platform as "DNA technologies." The graph below illustrates the dynamics in the cutting-edge sector of proteomics and biotechnology.
Broad Market Index - GURU.Markets
Quantum-Si is a biotech company that has developed a platform for analyzing proteins at the single-molecule level. Its breakthrough technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Quantum-Si compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
QSI - Daily change in the company's share price Quantum Si
Quantum-Si, a biotech company, is extremely volatile. Change_co measures the market reaction to news about its protein sequencing technology. This metric is an essential component in building valuation models for cutting-edge companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Quantum-Si Incorporated is a proteomics company. This chart illustrates the high volatility of the life sciences sector. Comparing it to QSI's performance helps us understand how much its growth depends on R&D budgets and the adoption of its technology in research labs.
Daily change in the price of a broad market stock, index - GURU.Markets
Quantum-Si is a company developing a next-generation proteomic sequencing platform. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Quantum-Si's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Quantum Si
Quantum-Si's year-over-year performance is a story of commercializing its proteomic sequencing platform. Its 12-month market cap depends entirely on the progress of installing its instruments in research labs. Every instrument sold is a fundamental step toward validating the potential of its unique protein analysis technology.
Annual dynamics of market capitalization of the market segment - Dna
Quantum-Si Incorporated is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough scientific potential rather than its current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quantum-Si, with its protein sequencing technology, is a speculative bet on the future of medicine. Its stock price is not tied to the economy, but rather driven by scientific breakthroughs and partnerships. The chart tells the story of investors' faith that its technology will revolutionize diagnostics and drug discovery.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Quantum Si
The market capitalization of Quantum-Si, a proteomics company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about progress in the commercialization of its unique protein analysis platform, which determines its future.
Monthly dynamics of market capitalization of the market segment - Dna
Quantum-Si aims to revolutionize biology by creating the world's first single-chip protein sequencing platform. The company's success depends on investment in research. The chart below shows how investors valued the entire biotech tools sector, providing an excellent backdrop for analyzing QSI's breakthrough technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Quantum-Si Incorporated is a company developing protein sequencing technology. Its shares represent a venture bet on a scientific breakthrough. Their performance is completely disconnected from market trends and driven by news about research progress and technological milestones, which implies extreme volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Quantum Si
Shares of Quantum-Si, a company developing a proteomic analysis platform, are extremely volatile. Weekly price movements reflect news about technological advances, scientific publications, and the potential adoption of their equipment in laboratories. The chart below illustrates how short-term events at the cutting edge of science influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Dna
How unique is Quantum-Si's performance in the biotech sector? This chart compares the company's weekly stock price movements with the overall sector trend. This helps us understand whether its move, driven by news about proteomic analysis, is a unique event on the cutting edge of science or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Quantum-Si is developing a next-generation proteomics platform for protein analysis. This chart compares its weekly volatility with the market. It shows how its stock, like other biotech companies, is driven by news about scientific breakthroughs rather than by overall market trends.
Market capitalization of the company, segment and market as a whole
QSI - Market capitalization of the company Quantum Si
Quantum-Si's valuation on the chart is a bet on its ambitious goal of creating the world's first protein sequencing chip. This early-stage biotech company's market cap reflects investors' faith in its potential to revolutionize proteomics. The dynamics illustrate the long and risky path from scientific idea to commercial product.
QSI - Share of the company's market capitalization Quantum Si within the market segment - Dna
Quantum-Si Incorporated is aiming to capture market share in proteomics with its next-generation protein sequencing platform. Its capitalization is a bet that its technology will revolutionize diagnostics and drug discovery, just like DNA sequencing.
Market capitalization of the market segment - Dna
Here's a chart of the total market capitalization of the biotech sector focused on proteomics and sequencing. Quantum-Si is one of the pioneers with this new technology. The graph highlights the enormous expectations surrounding this field, which has the potential to revolutionize drug development.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market valuation of a technology that promises to revolutionize protein research. Quantum-Si's market capitalization is a bet on its semiconductor chip for proteomics. The line shows how a breakthrough scientific idea, capable of accelerating drug development, shapes its value in the global economy.
Book value capitalization of the company, segment and market as a whole
QSI - Book value capitalization of the company Quantum Si
Quantum-Si's book value represents its scientific and technological capital. The chart below reflects the valuation of its patents, equipment, and developments in protein sequencing. The growth of the line reflects investments in the development and commercialization of breakthrough technology capable of changing the world of biomedical research.
QSI - Share of the company's book capitalization Quantum Si within the market segment - Dna
Quantum-Si's tangible assets are not production lines, but cutting-edge laboratories and equipment for developing a unique single-chip proteomic analysis platform. The chart shows its share of this high-tech scientific infrastructure, which is the physical core of its future innovations.
Market segment balance sheet capitalization - Dna
Below you can see the overall book value of the biotech sector. Against this backdrop, Quantum-Si, which is developing a next-generation proteomics platform, appears capital-intensive in its niche. The creation of complex scientific equipment requires significant investment in R&D and production, unlike "lightweight" software companies.
Book value of all companies included in the broad market index - GURU.Markets
Quantum-Si is developing a platform for proteomic sequencing—the "reading" of proteins. The company's assets are not factories, but patents, prototype devices, and scientific data. Their balance sheet represents investments in creating a "Google for proteins." Against the backdrop of the entire material economy, QSI is building a tool for understanding its most fundamental, biological basis.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Quantum Si
Quantum-Si's balance sheet consists of its cash and prototype protein analysis instruments. Its market capitalization reflects fading faith in its technology. The MvsBCap_Co chart, approaching one, shows that the market values the company at little more than the cash in its accounts, having almost completely written off its scientific "dreams."
Market to book capitalization ratio in a market segment - Dna
Quantum-Si is developing a next-generation proteomics platform for protein analysis. Its value lies in the potential of its technology to transform biomedical research. The chart reflects a high speculative valuation for its scientific breakthrough, not its current tangible assets.
Market to book capitalization ratio for the market as a whole
Quantum-Si develops a next-generation proteomic sequencing platform that enables protein analysis at the single-molecule level. The company's core value lies in its breakthrough technology. This chart clearly illustrates why companies operating at the forefront of biotechnology can have valuations far removed from their current book value.
Debts of the company, segment and market as a whole
QSI - Company debts Quantum Si
Quantum-Si, a biotech company developing a proteomic analysis platform, uses debt to fund cutting-edge research. This chart shows how the company is raising capital to commercialize its protein sequencing technology. In this breakthrough field of science, debt is an investment in a tool that can accelerate drug development.
Market segment debts - Dna
Quantum-Si is developing a next-generation proteomics platform, aiming to make protein analysis as accessible as DNA sequencing. This breakthrough technology requires significant investment in research and development. This chart shows how the company is funding its journey from a complex scientific concept to a commercial product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Quantum Si
Quantum-Si, a proteomics and protein analysis company, is at the forefront of a science-intensive industry. The chart shows how much it relies on debt to finance its expensive research and development. This high reliance on debt represents a significant risk if the commercialization of its unique technology fails to meet investor expectations.
Market segment debt to market segment book capitalization - Dna
Quantum-Si is developing a next-generation proteomic sequencing platform. This is a breakthrough technology in biomedical sciences, requiring colossal investments in R&D. The chart shows how this innovative company's debt load compares to the market capitalization and risks of the entire biotech sector.
Debt to book value of all companies in the market
#VALUE!
P/E of the company, segment and market as a whole
P/E - Quantum Si
This chart for Quantum-Si, a company developing a next-generation proteomic analysis (protein study) platform, is a measure of faith in a scientific breakthrough. There is no P/E ratio. The company's entire valuation is based on expectations that its technology will revolutionize biomedical research, not on current financial results.
P/E of the market segment - Dna
Here's the average P/E for biotech companies developing research equipment. Quantum-Si likely has no P/E. But this chart shows how companies creating tools for scientific breakthroughs are valued on average. It provides context for a valuation based on belief in the revolutionary potential of its technology.
P/E of the market as a whole
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. The company's technology has the potential to revolutionize biomedical research and diagnostics. This risk appetite chart helps understand how investors value companies creating breakthrough scientific tools.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Quantum Si
Quantum-Si is developing a next-generation proteomics platform that will enable protein analysis at the single-molecule level. This graph reflects expectations for a breakthrough in biomedical research. The valuation is purely speculative and depends on investors' belief that the company's technology will become a new standard in protein analysis.
%20P%2FE%20Quantum%20Si&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Quantum-Si&v=1772513594934 "Chart of the company's future (projected) P/E Quantum Si")
Future (projected) P/E of the market segment - Dna
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. This chart reflects the company's long-term profitability expectations compared to other biotech companies. It demonstrates how highly the market values the potential of their technology for scientific discovery and diagnostics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513594935 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Quantum-Si is developing a next-generation proteomics platform for protein analysis. This breakthrough technology is in the early stages of commercialization. This graph of overall market expectations reflects investor willingness to fund science-intensive and risky projects. Market optimism increases access to capital for such companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513594936 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Quantum Si
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. The company is in the commercialization stage of its technology. Its financial performance reflects significant investments in R&D. This chart shows the path of this breakthrough scientific technology to market.
Profit of companies in the market segment - Dna
Quantum-Si is developing a next-generation proteomics platform capable of analyzing proteins at the single-molecule level. The company is in the early stages of commercialization. This graph reflects the massive investment in the life sciences sector, where breakthrough technologies require significant R&D before they can contribute to overall industry profitability.
Overall market profit
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. The company is at the forefront of the biotech revolution. Its success depends on scientific breakthroughs and market adoption, not on the short-term economic cycles that shape the overall picture in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Quantum Si
Quantum-Si aims to revolutionize proteomics with its single-chip protein sequencing platform. This chart reflects analyst expectations based on the potential of this breakthrough technology. These forecasts are dependent on the platform's commercial adoption by research institutions and pharmaceutical companies.
%20profit%20of%20the%20company%20Quantum%20Si&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Quantum-Si&v=1772513594947 "Graph of future (projected) profit of the company Quantum Si")
Future (predicted) profit of companies in the market segment - Dna
Quantum-Si is developing a next-generation protein sequencing platform, aiming to make proteomics more accessible. This chart shows the revenue forecast for the entire DNA and protein analysis industry. It reflects the expected growth of the biotech research market, a key factor in assessing the potential demand for Quantum-Si's innovative technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513594954 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Quantum-Si is developing a next-generation proteomics (protein analysis) platform. As a cutting-edge biotechnology company, its success depends on R&D funding and the acceptance of its technology by the scientific community. The overall economic environment, illustrated here, influences the level of public and private investment in fundamental science.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513594963 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Quantum Si
Quantum-Si is developing a next-generation proteomics (protein analysis) platform that promises to accelerate scientific research and drug development. The company doesn't yet have significant revenue. This chart shows how investors value its breakthrough technology, pricing it based on the enormous potential of the future protein analysis market rather than current sales.
P/S market segment - Dna
Quantum-Si is a biotechnology company developing the world's first next-generation protein sequencing platform. This technology has the potential to revolutionize biomedical research and diagnostics. This chart shows the average valuation in the sector, helping to understand the market premium placed on the potential breakthrough and commercialization of Quantum-Si's technology.
P/S of the market as a whole
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. This is a breakthrough technology for biomedical research. This chart compares the high revenue estimates of this high-tech company with the more down-to-earth metrics of companies in traditional sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Quantum Si
Quantum-Si is developing a next-generation protein sequencing platform. As an early-stage company with no significant revenue, its valuation is based entirely on future potential. This chart reflects the market's belief that its technology will revolutionize research and be successfully commercialized.
%20P%2FS%20Quantum%20Si&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Quantum-Si&v=1772513594977 "The graph of the company's future (projected) P/S Quantum Si")
Future (projected) P/S of the market segment - Dna
Quantum-Si is developing a next-generation proteomics platform designed to analyze proteins at the single-molecule level. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. This valuation reflects investor confidence in its breakthrough technology for scientific research and diagnostics.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513594978 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Quantum-Si is developing a next-generation proteomics platform for protein analysis. This is a bet on the future of biotechnology. The market optimism reflected in this chart is based on faith in scientific breakthroughs. Quantum-Si is creating a tool that can accelerate these breakthroughs in drug development, and its potential is part of this high expectation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513594980 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Quantum Si
Quantum-Si is developing a next-generation proteomics (protein analysis) platform based on a semiconductor chip. Currently in the early stages of commercialization, the company's revenue is generated from sales of initial instruments and consumables. The chart shows the initial revenue from the implementation of its breakthrough technology in research laboratories.
Sales of companies in the market segment - Dna
Quantum-Si is a biotechnology company developing the world's first next-generation protein sequencing platform. This technology is destined to revolutionize biomedical research and diagnostics. Currently, the company's revenue is negligible and is primarily driven by initial sales. This chart illustrates the potential of the proteomics market, where Quantum-Si is a key pioneer.
Overall market sales
Quantum-Si is developing a next-generation proteomics platform for studying proteins. This cutting-edge scientific technology is in demand from research institutes and pharmaceutical companies. Its business depends on investment in science, which, in turn, is indirectly linked to overall economic prosperity, as reflected in this graph.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Quantum Si
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. The company is in the early stages of commercialization. This timeline reflects analysts' expectations for the adoption of this cutting-edge technology in scientific research and pharmaceuticals, which will determine future demand for Quantum-Si products.
%20sales%20of%20the%20company%20Quantum%20Si&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Quantum-Si&v=1772513594989 "Schedule of future (projected) sales of the company Quantum Si")
Future (projected) sales of companies in the market segment - Dna
Quantum-Si is developing a next-generation proteomics platform designed for protein analysis. This chart reflects forecasts for the DNA and protein research sector. It allows one to assess the revolutionary nature of the company's technology and how its commercialization could impact growth compared to established players in the life sciences market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513594990 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Quantum-Si is developing a next-generation proteomics platform for protein analysis. This chart, reflecting investments in biotechnology and pharmaceutical research, is important to the company. Growing R&D funding is encouraging scientific labs and pharmaceutical companies to implement advanced analytical tools to accelerate drug development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513594990 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Quantum Si
Quantum-Si is at the forefront of biotechnology, developing the world's first single-chip protein sequencing platform. The company's focus is on scientific research and commercialization of breakthrough technology. This chart reflects the current phase of significant R&D investment required to bring a product to market that could transform science.
Market segment marginality - Dna
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. This is a breakthrough technology for medical research. While the company is in the commercialization stage, it is incurring significant costs. This chart reflects the level of investment in launching a technology that could change the scientific landscape.
Market marginality as a whole
Quantum-Si aims to revolutionize proteomics by developing the world's first single-chip protein sequencing platform. The overall profitability picture is irrelevant to them. This is a venture capital bet on creating an entirely new market. Success depends solely on whether their technology works and whether it is adopted by the scientific community.
Employees in the company, segment and market as a whole
Number of employees in the company Quantum Si
Quantum-Si is developing a next-generation protein sequencing platform, aiming to make proteomics more accessible. This graph shows the team of scientists and engineers. The growth in staff directly reflects the investment in this breakthrough technology and the efforts to bring it from the lab to the commercial market.
Share of the company's employees Quantum Si within the market segment - Dna
Quantum-Si is revolutionizing proteomics by developing the world's first single-chip protein sequencing platform. This chart shows the percentage of leading scientists in this cutting-edge field that the company attracts. It's a testament to its scientific leadership and the scale of the team working to create a tool that will transform biology and medicine.
Number of employees in the market segment - Dna
Quantum-Si is developing a next-generation proteomics platform that enables protein analysis at the single-molecule level. The graph shows the growth of employment in the life sciences sector. The growing number of scientists and engineers in this cutting-edge field reflects the race to create tools that can revolutionize diagnostics and drug development.
Number of employees in the market as a whole
Quantum-Si is revolutionizing proteomics by developing the world's first single-chip protein sequencing platform. This is a breakthrough technology for medicine and biotechnology. This graph shows overall employment, and companies like Quantum-Si represent the vanguard of the innovation economy, creating unique jobs for highly skilled scientists and engineers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Quantum Si (QSI)
Quantum-Si Incorporated is developing a next-generation proteomics platform. It's a science-intensive business, where all the value is locked into the potential of breakthrough technology. This chart vividly illustrates the model's extremely high capitalization per employee. Investors value not current revenue, but the future opportunities that a small team of highly qualified scientists can create.
%20of%20the%20company%20Quantum%20Si%20(QSI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Quantum-Si-QSI&v=1772513595019 "Chart of market capitalization per employee (in thousands of dollars) of the company Quantum Si (QSI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Quantum-Si is developing a next-generation proteomic sequencing platform. For a life science company whose value lies in breakthrough technology, this metric reflects the market's confidence in its scientific potential. The graph shows how investors value each employee's contribution to the future revolution in protein analysis, compared to other innovators.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513595019 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Quantum-Si is developing breakthrough protein sequencing technology that could revolutionize medicine and biotechnology. This chart reflects the enormous market value per employee, typical of companies at the forefront of science. It demonstrates investors' faith in the technology's potential to transform scientific research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513595020 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Quantum Si (QSI)
Quantum-Si (QSI) is a biotech company developing the world's first single-chip protein sequencing platform. This is deep R&D. This chart shows the "cost" of breakthrough research: it measures the negative profit (R&D costs) per highly qualified scientist and engineer working on this revolutionary technology.
%20Chart%20Quantum%20Si%20(QSI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Quantum-Si-QSI&v=1772513595021 "Company Profit Per Employee (in thousands of dollars) Chart Quantum Si (QSI)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Quantum-Si is working on a protein analysis platform (proteomics). They are developing a chip for "reading" proteins, similar to DNA sequencers. This graph shows the benchmark for personnel efficiency in biotech. It is important for assessing how effectively Quantum-Si's scientific team is using capital to create this breakthrough technology.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513595024 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Quantum-Si is a life sciences company developing a next-generation proteomics (protein analysis) platform. They are at the intersection of biotech and high tech. During the R&D and product launch phases, this graph will likely show a negative value. It reflects the investment per employee required to create a technology that has the potential to transform the scientific research market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513595034 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Quantum Si (QSI)
Quantum-Si is developing a next-generation proteomics platform capable of analyzing proteins at the single-molecule level. This graph reflects the early stages of commercialization. Low revenue per employee is typical for companies bringing breakthrough scientific technology to market. The current focus is on implementing the platform in research labs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Quantum-Si-QSI&v=1772513595036 "Sales chart per company employee Quantum Si (QSI)")
Sales per employee in the market segment - Dna
Quantum-Si (QSI) is a biotechnology company developing the world's first single-chip protein sequencing platform. This is at the forefront of R&D. This graph shows the revenue (currently minimal) generated by each employee (scientist). It reflects the stage of commercialization of their breakthrough technology compared to other scientific instrument manufacturers.
Sales per employee for the market as a whole
Quantum-Si is a company aiming to revolutionize proteomics (the study of proteins). They are developing a platform for on-chip protein sequencing. They are a high-tech R&D company in the commercialization stage. This graph is close to zero, indicating that the company is comprised of scientists and engineers and is in the technology investment stage, not generating commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Quantum Si (QSI)
Quantum-Si is a biotech company attempting to commercialize a protein sequencing platform. It's a very early and risky stage. This chart shows bearish bets. The shorts are driven by high cash burn and doubts about the company's ability to achieve commercial success and outperform competitors in the complex field of proteomics.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Quantum-Si-QSI&v=1772513595044 "Short Shares Chart for the Company Quantum Si (QSI)")
Shares shorted by market segment - Dna
Quantum-Si (QSI) is a biotech company aiming to create the world's first single-chip protein sequencing (proteomics) platform. This chart shows bets against the entire "scientific instrumentation" sector. Its rise reflects investor skepticism about the commercialization of this complex technology and concerns that R&D budgets for laboratories (QSI's clients) will be cut.
Shares shorted by the overall market
Quantum-Si (QSI) is developing a next-generation proteomics (protein analysis) platform. It's an early-stage, science-intensive company, a "growth story" without profits. This market panic chart shows when investors flee such risky assets. For QSI, market panic means a sharp decline in shares and difficulties raising capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Quantum Si (QSI)
Quantum-Si is a company developing a desktop platform for proteomics (protein analysis) on a chip. This is a groundbreaking, yet speculative, R&D bet. This chart measures the level of hype. It shows when euphoria (overbought) or doubts about the technology (oversold) reach a peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Quantum-Si-QSI&v=1772513595047 "RSI 14 indicator chart for the company's stock Quantum Si (QSI)")
RSI 14 Market Segment - Dna
Quantum-Si is a biotech company developing a next-generation proteomics (protein study) platform. Their goal is to create the world's first protein sequencing chip. This chart measures the collective excitement in the life sciences sector. It helps us understand whether the entire speculative segment is overheated by expectations of a breakthrough.
RSI 14 for the overall market
Quantum-Si, a company developing the "future" (protein sequencing), is pure R&D. This chart is its lifeline. During periods of euphoria, investors are willing to generously fund unprofitable but breakthrough "growth stories." In moments of panic, the money supply is turned off, and speculative companies risk being left without funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast QSI (Quantum Si)
Quantum-Si is a life science company developing the world's first single-chip protein sequencing platform. This chart reflects the collective opinion of experts. Their forecasts are based not on current revenues, but on an assessment of the potential of this breakthrough technology and its speed of adoption in scientific laboratories.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-QSI-Quantum-Si&v=1772513595060 "A chart showing analyst consensus forecasts for the expected stock price. QSI (Quantum Si)")
The difference between the consensus estimate and the actual stock price QSI (Quantum Si)
Quantum-Si (QSI) is an R&D-stage biotech company developing a desktop protein sequencing platform. This is a pure R&D bet. This chart reflects these high risks. It measures the gap between the price and the consensus target, showing the enormous (but speculative) potential analysts see if their technology is successful.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-QSI-Quantum-Si&v=1772513595062 "A chart showing the difference between the consensus forecast and the actual stock price. QSI (Quantum Si)")
Analyst consensus forecast for stock prices by market segment - Dna
Quantum-Si is a biotech company developing single-chip protein sequencing (proteomics). It's betting on the next big scientific breakthrough after DNA. This chart shows analysts' overall expectations for the DNA (and proteomics) sector. It reflects whether experts believe this complex R&D platform will be commercialized.
Analysts' consensus forecast for the overall market share price
Quantum-Si is a biotech company working on the world's first protein sequencing platform. This is fundamental science with enormous potential, but also high risk. This chart shows the overall risk appetite in the market. For QSI, as an early-stage company, overall market optimism (as the chart rises) is critical for funding long-term and expensive R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Quantum Si
Quantum-Si (QSI) is a biotech company working on the edge of the impossible. They are developing the world's first proteomic sequencing (protein analysis) platform on a single chip. They are betting on the next step beyond DNA. This chart is a pure indicator of faith in their futuristic R&D. It doesn't reflect revenue, but rather a speculative assessment of their scientific progress and their chances of commercialization.
AKIMA Market Segment Index - Dna
Quantum-Si operates at the forefront of biotechnology, developing a protein sequencing platform. It is a highly research-intensive business. This chart shows the average index for the Life Sciences segment. It provides investors with a benchmark for how the aggregate performance of Quantum-Si, a company at the intersection of science and commerce, compares to the average performance and risk profile of the sector.
The AKIM Index for the overall market
Quantum-Si is a company developing semiconductor chips for protein sequencing (proteomics). This is the next frontier after genomics. This chart, reflecting the market average, is a backdrop. It helps assess how this speculative technology story, currently in the commercialization stage, stacks up against overall macroeconomic trends and risk appetite.
